\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}



\usepackage{float}








\begin{document}

\title{Seroprevalence and Clinical Characteristics of SARS-CoV-2 Infection in
Children with Cystic Fibrosis}



\author[1]{Georgene Hergenroeder}%
\author[2]{Anna Faino}%
\author[1]{Jonathan Cogen}%
\author[1]{Alan Genatossio}%
\author[1]{Sharon McNamara}%
\author[1]{Michael Pascual}%
\author[1]{Rafael Hernandez}%
\affil[1]{Seattle Children's Hospital}%
\affil[2]{Seattle Children's Research Institute}%


\vspace{-1em}



  
  \date{May 18, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
\textbf{Background:} People with cystic fibrosis (PwCF) have chronic
lung disease and may be at increased risk of COVID-19-related morbidity
and mortality. This study aimed to determine seroprevalence and clinical
characteristics of SARS-CoV-2 infection in children with CF, and to
assess antibody responses following SARS-CoV-2 infection or vaccination.
\textbf{Methods:} Children and adolescents with CF followed at Seattle
Children's Hospital were enrolled between July 20, 2020 and February 28,
2021. SARS-CoV-2 serostatus was determined on enrollment, at 6 and 11
months (+/-2 months) for nucleocapsid and spike IgG. Participants
completed intake and weekly surveys inquiring about SARS-CoV-2
exposures, viral/respiratory illnesses, and symptoms. \textbf{Results:}
Of 125 PwCF enrolled, 14 (11\%) had positive SARS-CoV-2 antibodies
consistent with recent or past infection. Seropositive participants were
more likely to identify as Hispanic (29\% vs 8\%, p=0.04) and have
pulmonary exacerbations requiring oral antibiotics in the year prior
(71\% vs 41\%, p = 0.04). Five seropositive individuals (35.7\%) were
asymptomatic, while six (42.9\%) reported mild symptoms, primarily cough
and nasal congestion. Anti-spike protein IgG levels were approximately
10-fold higher in participants following vaccination compared with
participants who had natural infection alone (p \textless{} 0.0001) and
resembled levels previously reported in the general population.
\textbf{Conclusions:} A majority of PwCF have mild or no symptoms of
SARS-CoV-2 making it difficult to distinguish from baseline respiratory
symptoms. Hispanic PwCF may be disproportionately impacted, consistent
with racial and ethnic COVID-19 disparities among the general US
population. Vaccination in PwCF generated antibody responses similar to
those previously reported in the general population.%
\end{abstract}%



\sloppy


\textbf{Hosted file}

\verb`Hergenroeder_2023_03_15_PedsPulm.docx`  available at \url{https://authorea.com/users/597936/articles/630754-seroprevalence-and-clinical-characteristics-of-sars-cov-2-infection-in-children-with-cystic-fibrosis}

\selectlanguage{english}
\FloatBarrier
\end{document}

